GlassScriptPhysician profile
Rebecca Mattison
NPI 1093775736
$2,245.78
in general payments reported to CMS, 2019-2025
37 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $193 · 2021: $295 · 2022: $258 · 2023: $477 · 2024: $439 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,251.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $220.41 | 2022-2025 | Intellis Adaptivestim, Minimed 780g, Inceptiv |
| Alexion Pharmaceuticals, INC. | $193.32 | 2019-2025 | Strensiq |
| Amgen INC. | $192.77 | 2019-2025 | Tepezza, Repatha |
| Insulet Corporation | $164.99 | 2019-2025 | Omnipod |
| Abbott Laboratories | $142.24 | 2022-2025 | Freestyle Libre 3 |
| Ipsen Biopharmaceuticals, INC | $111.53 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.53 | 2019-2024 | Jardiance |
| Dexcom, INC. | $86.09 | 2020-2023 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $72.50 | 2020-2024 | Nexletol |
| Radius Health, INC. | $69.70 | 2020-2024 | Tymlos |
| Recordati_rare_diseases_inc. | $60.17 | 2025 | Isturisa |
| Antares Pharma, INC. | $59.70 | 2022-2025 | Xyosted |
| Mannkind Corporation | $58.76 | 2023-2025 | Afrezza |
| Ascensia Diabetes Care US INC. | $49.77 | 2023-2024 | |
| Medtronic Minimed, INC. | $48.48 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $48.10 | 2023 | Korlym |
| Novo Nordisk INC | $46.31 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.71 | 2024-2025 | |
| Horizon Therapeutics Plc | $39.41 | 2021-2022 | |
| Chiesi USA, INC. | $37.30 | 2024-2025 | Mycapssa |
| Lilly USA, LLC | $36.11 | 2023-2024 | Zepbound, Lyumjev |
| Pfizer INC. | $34.84 | 2025 | |
| Valeritas, INC. | $32.85 | 2019 | |
| Novartis Pharmaceuticals Corporation | $30.67 | 2023 | |
| Kyowa Kirin, INC. | $29.45 | 2023 | Crysvita |
| Xeris Pharmaceuticals, INC. | $28.70 | 2020-2022 | |
| Lifescan, INC. | $27.72 | 2021 | |
| Companion Medical, INC. | $27.21 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $24.06 | 2021 | |
| Zealand Pharma US, INC. | $19.33 | 2021 | |
| Halozyme INC | $19.22 | 2023 | |
| Ionis Pharmaceuticals, INC. | $17.27 | 2025 | Tryngolza |
| Cequr Corporation | $16.63 | 2025 | Cequr Simplicity |
| Sequel Med Tech, LLC | $16.55 | 2025 | Twiist |
| Rhythm Pharmaceuticals, INC. | $14.54 | 2023 | Imcivree |
| Tandem Diabetes Care, INC. | $12.23 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Mattison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.